Evidence map›Paper›PMID 36504385›Full record

ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2023

Familial atrial fibrillation mutation M1875T-SCN5A increases early sodium current and dampens the effect of flecainide.

Molly O'Reilly, Laura C Sommerfeld, C O'Shea, S Broadway-Stringer, S Andaleeb, J S Reyat, S N Kabir, D Stastny, A Malinova, D Delbue and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Discovery ofDiagnostics (Basel, Switzerland) · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Identification and Functional Investigation ofDiagnostics (Basel, Switzerland) · 2024
    Article
  8. Optical mapping and optogenetics in cardiac electrophysiology research and therapy: a state-of-the-art review.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Review
  9. Review
  10. 25 years of basic and translational science in EP Europace: novel insights into arrhythmia mechanisms and therapeutic strategies.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Review
  11. The opioid tramadol blocks the cardiac sodium channel Nav1.5 in HEK293 cells.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Article
  12. Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 3 countries.

Molly O'ReillyInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Wolfson Drive, Birmingham B15 2TT, UK.ORCID 0000-0003-1936-5838
Laura C SommerfeldInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Wolfson Drive, Birmingham B15 2TT, UK.ORCID 0000-0001-9837-8770
C O'SheaInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Wolfson Drive, Birmingham B15 2TT, UK.ORCID 0000-0003-3030-7364
S Broadway-StringerInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Wolfson Drive, Birmingham B15 2TT, UK.ORCID 0000-0003-1657-5442
S AndaleebInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Wolfson Drive, Birmingham B15 2TT, UK.ORCID 0000-0001-8264-3664
J S ReyatInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Wolfson Drive, Birmingham B15 2TT, UK.ORCID 0000-0003-3247-9186
S N KabirInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Wolfson Drive, Birmingham B15 2TT, UK.ORCID 0000-0003-1811-8683
D StastnyUniversity Center of Cardiovascular Science, University Heart and Vascular Center, UKE Hamburg, Martinistraße 52, Hamburg 20246, Germany.ORCID 0000-0001-5986-8830
A MalinovaInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Wolfson Drive, Birmingham B15 2TT, UK.ORCID 0000-0003-0325-501X
D DelbueUniversity Center of Cardiovascular Science, University Heart and Vascular Center, UKE Hamburg, Martinistraße 52, Hamburg 20246, Germany.ORCID 0000-0001-9534-1884
L FortmuellerUniversity Center of Cardiovascular Science, University Heart and Vascular Center, UKE Hamburg, Martinistraße 52, Hamburg 20246, Germany.
K GehmlichInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Wolfson Drive, Birmingham B15 2TT, UK.ORCID 0000-0003-4019-1844
D PavlovicInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Wolfson Drive, Birmingham B15 2TT, UK.ORCID 0000-0002-3171-3551
B V SkryabinMedical Faculty, Core Facility Transgenic animal and genetic engineering Models (TRAM), University of Muenster, Muenster, Germany.ORCID 0000-0002-4392-185X
A P HolmesInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Wolfson Drive, Birmingham B15 2TT, UK.ORCID 0000-0001-9270-9401
P KirchhofInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Wolfson Drive, Birmingham B15 2TT, UK.ORCID 0000-0002-1881-0197
L FabritzInstitute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Wolfson Drive, Birmingham B15 2TT, UK.ORCID 0000-0002-9241-1733
University of Birmingham · GBUniversität Hamburg · DEAmsterdam UMC Location University of Amsterdam · NLBritish Heart Foundation · GBUniversity of Münster · DE

Funding

British Heart Foundation AA/18/2/34218British Heart Foundation FS/12/40/29712British Heart Foundation FS/13/43/30324British Heart Foundation PG/17/30/32961Medical Research Council MR/V009540/1Medical Research Council V009540/1Wellcome TrustWellcome Trust 201543/B/16/ZWellcome Trust 201543/B/16/Z; 221650/Z/20/Z
6 · The paper itself

Abstract

aimsAtrial fibrillation (AF) is the most common cardiac arrhythmia. Pathogenic variants in genes encoding ion channels are associated with familial AF. The point mutation M1875T in the SCN5A gene, which encodes the α-subunit of the cardiac sodium channel Nav1.5, has been associated with increased atrial excitability and familial AF in patients. METHODS AND

resultsWe designed a new murine model carrying the Scn5a-M1875T mutation enabling us to study the effects of the Nav1.5 mutation in detail in vivo and in vitro using patch clamp and microelectrode recording of atrial cardiomyocytes, optical mapping, electrocardiogram, echocardiography, gravimetry, histology, and biochemistry. Atrial cardiomyocytes from newly generated adult Scn5a-M1875T+/- mice showed a selective increase in the early (peak) cardiac sodium current, larger action potential amplitude, and a faster peak upstroke velocity. Conduction slowing caused by the sodium channel blocker flecainide was less pronounced in Scn5a-M1875T+/- compared to wildtype atria. Overt hypertrophy or heart failure in Scn5a-M1875T+/- mice could be excluded.

conclusionThe Scn5a-M1875T point mutation causes gain-of-function of the cardiac sodium channel. Our results suggest increased atrial peak sodium current as a potential trigger for increased atrial excitability.

Indexed as

Atrial FibrillationAnimalsFlecainideHeart AtriaMiceMutationNAV1.5 Voltage-Gated Sodium ChannelFlecainideNAV1.5 Voltage-Gated Sodium ChannelSCN5A protein, humanScn5a protein, mouseAtrial electrophysiologyChannelopathySodium channelSodium channel blocker

Identifiers

PMID36504385
PMCPMC10062360
OpenAlexW4311205253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.